We are live on ! Find out more
ELTX icon

Elicio Therapeutics
ELTX

17 hedge funds and large institutions have $2.25M invested in Elicio Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.35% less ownership

Funds ownership: 4.56% → 4.21% (-0.35%)

6% less funds holding

Funds holding: 18 → 17 (-1)

9% less capital invested

Capital invested by funds: $2.48M → $2.25M (-$225K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.76K
2
BlackRock
BlackRock
New York
+$581
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$320

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$64.7K
2
BCM
Bridgeway Capital Management
Texas
-$62.9K
3
CM
CM Management
Florida
-$49.2K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.2K
5
UBS Group
UBS Group
Switzerland
-$4.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.2M +$2.76K +561 +0.2%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$347K -$4.2K -853 -1%
CM
3
CM Management
Florida
$204K -$49.2K -10,000 -20%
Northern Trust
4
Northern Trust
Illinois
$157K – – –
State Street
5
State Street
Massachusetts
$107K – – –
BlackRock
6
BlackRock
New York
$101K +$581 +118 +0.6%
MHC
7
Meyer Handelman Company
New York
$70.9K – – –
CIBC Private Wealth Group
8
CIBC Private Wealth Group
Georgia
$42.6K – – –
SPIA
9
Steward Partners Investment Advisory
New York
$7.92K – – –
Bank of America
10
Bank of America
North Carolina
$6.11K -$192 -39 -3%
TRCT
11
Tower Research Capital (TRC)
New York
$3.12K -$1.67K -339 -36%
Citigroup
12
Citigroup
New York
$1.83K – – –
Morgan Stanley
13
Morgan Stanley
New York
$1.17K -$49 -10 -4%
SS
14
SBI Securities
Japan
$423 +$409 +83 New
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$332 +$320 +65 New
JP Morgan Chase
16
JP Morgan Chase
New York
$88 – – –
UBS Group
17
UBS Group
Switzerland
$87 -$4.09K -831 -98%
Citadel Advisors
18
Citadel Advisors
Florida
– -$64.7K -12,856 Closed
BCM
19
Bridgeway Capital Management
Texas
– -$62.9K -12,500 Closed
National Bank of Canada
20
National Bank of Canada
Quebec, Canada
– -$4.02K -800 Closed

ELTX Hedge Fund Activity: Q4 2024 in Review

17 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2024, worth a combined $2.25M — down 9.1% from $2.48M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ELTX and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $2.76K. The largest seller was Citadel Advisors, exiting entirely with an estimated $64.7K sold.

  • 17 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2024, down from 18 in Q3 2024.
  • Funds reported $2.25M of Elicio Therapeutics stock for Q4 2024, down 9.1% quarter-over-quarter.
  • 2 funds opened new Elicio Therapeutics positions in Q4 2024 and 3 closed out, a net change of -1 holder.
  • The largest Elicio Therapeutics buyer in Q4 2024 was Vanguard Group, an estimated $2.76K added.
  • The largest Elicio Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $64.7K sold.

Based on aggregated 13F filings for Q4 2024.